Market Cap
US$1.7b
Last Updated
2021/02/24 23:41 UTC
Data Sources
Company Financials +
Executive Summary
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. More Details
Rewards
Risk Analysis
Earnings are forecast to decline by an average of 19.2% per year for the next 3 years
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet and fair value.
Similar Companies
Share Price & News
How has REGENXBIO's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RGNX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: RGNX's weekly volatility (8%) has been stable over the past year.
Market Performance
7 Day Return
-8.4%
RGNX
0%
US Biotechs
0%
US Market
1 Year Return
-13.7%
RGNX
0%
US Biotechs
0%
US Market
Return vs Industry: RGNX underperformed the US Biotechs industry which returned 34.5% over the past year.
Return vs Market: RGNX underperformed the US Market which returned 34.1% over the past year.
Shareholder returns
| RGNX | Industry | Market | |
|---|---|---|---|
| 7 Day | -8.4% | 0% | 0% |
| 30 Day | -8.9% | 0% | 0% |
| 90 Day | 15.0% | 0% | 0% |
| 1 Year | -13.7%-13.7% | 0%0% | 0%0% |
| 3 Year | 44.0%44.0% | 0%0% | 0%0% |
| 5 Year | 218.9%218.9% | 0%0% | 0%0% |
Long-Term Price Volatility Vs. Market
How volatile is REGENXBIO's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is REGENXBIO undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: RGNX ($40.98) is trading below our estimate of fair value ($109)
Significantly Below Fair Value: RGNX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: RGNX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: RGNX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RGNX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RGNX is good value based on its PB Ratio (3.7x) compared to the US Biotechs industry average (4.3x).
Next Steps
Future Growth
How is REGENXBIO forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
-19.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RGNX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RGNX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RGNX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RGNX's revenue is expected to decline over the next 3 years (-5.4% per year).
High Growth Revenue: RGNX's revenue is forecast to decline over the next 3 years (-5.4% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RGNX is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has REGENXBIO performed over the past 5 years?
-12.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RGNX is currently unprofitable.
Growing Profit Margin: RGNX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RGNX is unprofitable, and losses have increased over the past 5 years at a rate of 12% per year.
Accelerating Growth: Unable to compare RGNX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RGNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-37%).
Return on Equity
High ROE: RGNX has a negative Return on Equity (-22.01%), as it is currently unprofitable.
Next Steps
Financial Health
How is REGENXBIO's financial position?
Financial Position Analysis
Short Term Liabilities: RGNX's short term assets ($387.0M) exceed its short term liabilities ($63.6M).
Long Term Liabilities: RGNX's short term assets ($387.0M) exceed its long term liabilities ($61.9M).
Debt to Equity History and Analysis
Debt Level: RGNX is debt free.
Reducing Debt: RGNX had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RGNX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: RGNX has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 22.2% each year.
Next Steps
Dividend
What is REGENXBIO current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RGNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RGNX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RGNX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RGNX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RGNX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.2yrs
Average management tenure
CEO
Ken Mills (45 yo)
11.92yrs
Tenure
US$6,147,269
Compensation
Mr. Kenneth T. Mills, also known as Ken, has been the Chief Executive Officer and President at REGENXBIO Inc. since March 2009. Mr. Mills served as the Chief Financial Officer and Vice President of Busines...
CEO Compensation Analysis
Compensation vs Market: Ken's total compensation ($USD6.15M) is above average for companies of similar size in the US market ($USD3.68M).
Compensation vs Earnings: Ken's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 11.92yrs | US$6.15m | 0.57% $ 9.8m | |
| Chief Financial Officer | 11.5yrs | US$2.18m | 0.24% $ 4.1m | |
| Chief Legal Officer | 4.5yrs | US$1.83m | 0.0061% $ 105.4k | |
| Chief Scientific Officer | 3.92yrs | US$1.93m | 0.018% $ 305.0k | |
| Chief Medical Officer | 1.83yrs | US$4.01m | 0% $ 0 | |
| Chief Operations & Technology Officer | no data | US$1.90m | 0.0093% $ 161.8k | |
| Vice President of Investor Relations & Corporate Communications | no data | no data | no data | |
| Vice President of Corporate Development | 3.92yrs | no data | no data | |
| Chief People Officer | 3.33yrs | no data | no data | |
| Senior Vice President of Intellectual Property | 4.75yrs | no data | no data | |
| Senior VP of Commercial Strategy & Operations | 2.5yrs | no data | no data | |
| Vice President of Law and Policy | 4.5yrs | no data | no data |
4.2yrs
Average Tenure
51.5yo
Average Age
Experienced Management: RGNX's management team is considered experienced (4.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 11.92yrs | US$6.15m | 0.57% $ 9.8m | |
| Independent Director | 5.33yrs | US$323.32k | 0% $ 0 | |
| Independent Director | 4.5yrs | US$318.32k | 0% $ 0 | |
| Lead Independent Director | 0.58yr | US$317.82k | 0% $ 0 | |
| Member of Scientific Advisor | no data | no data | no data | |
| Independent Director | 5.83yrs | US$333.32k | 0% $ 0 | |
| Chairman of the Board | 0.58yr | US$309.32k | 7.19% $ 124.7m | |
| Member of Scientific Advisor | no data | no data | no data | |
| Independent Director | 2.75yrs | US$312.83k | 0% $ 0 | |
| Independent Director | 4.5yrs | US$315.32k | 0% $ 0 |
4.5yrs
Average Tenure
66.5yo
Average Age
Experienced Board: RGNX's board of directors are considered experienced (4.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.7%.
Top Shareholders
Company Information
REGENXBIO Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: REGENXBIO Inc.
- Ticker: RGNX
- Exchange: NasdaqGS
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.734b
- Shares outstanding: 42.31m
- Website: https://www.regenxbio.com
Number of Employees
Location
- REGENXBIO Inc.
- 9600 Blackwell Road
- Suite 210
- Rockville
- Maryland
- 20850
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| RGNX | NasdaqGS (Nasdaq Global Select) | Yes | Common Shares | US | USD | Sep 2015 |
| RB0 | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Sep 2015 |
Biography
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic p...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/02/24 23:41 |
| End of Day Share Price | 2021/02/24 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.